Boehringer announcement confirms NASH race
Boehringer Ingelheim’s entry into the market for drugs to treat nonalcoholic fatty liver shows that a race is on in the lucrative field, says Danske Capital. The German group has an edge over Novo Nordisk, which is currently considering its entry in the segment.
BY STEFAN SINGH KAILAY
Novo Nordisk is still officially mulling over a decision to go actively into the area for therapies against Nonalcoholic Steatohepatitis (NASH) also known as nonalcoholic fatty liver disease – a market that could be worth billions – after independent researchers recently presented positive results highlighting the effect Novo’s liraglutide, the active substance in Victoza and Saxenda, has on the affliction.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches obesity drug in the US
For abonnenter
Novo wins approval of obesity drug in Europe
For abonnenter
